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September 21, 2010:1065–70atients in our trial had normal serum creatinine at baseline. In the
verall study 19% had impaired creatinine clearance at baseline of
60 ml/min, and there were no or even numerically worse effects
25% vs. 13%) of NAC on contrast agent-induced nephropathy
CIN) in this specific subgroup—demonstrated in Figure 2 of the
ublication (1). Performing a clinical trial with selection of patients
ith elevated serum creatinine 140 mol/l is not feasible,
ecause the serum creatinine is usually not known at hospital
resentation and waiting until laboratory results are available is
ertainly not possible, given the strong relationship of time-to-
eperfusion on myocardial salvage (2). Although, overall, there was
6% CIN reduction by NAC, the lack of effect in patients with
mpaired renal function raises doubts that there might be effects in
ifferent patient groups. Second, regarding the NAC dose, we
elieve that in total 6,000 mg is a high dose as shown previously
3), and there are currently no clinical trials that have tested higher
oses (4). Nevertheless, testing an even higher dose might be
orth study. Third, the distribution of NAC between the 2 target
rgans in our trial is indeed not entirely clear. However, local drug
oncentration measurement is clinically not feasible, and also local
rug application into the renal or the infarct-related artery is
onsidered impractical. Given the fast distribution through the
irculation, any relevant impairment of drug distribution is un-
ikely. Fourth, the 20% reduction in oxidative stress is interesting;
owever, its effect on clinically relevant parameters such as myo-
ardial salvage or renal function remains unclear. Because the
istribution of angiotensin-converting enzyme inhibitors, angio-
ensin II type 1 antagonists, and statins was similar between both
roups (Table 1 of Thiele et al. [1]), effects on oxidative stress are
nlikely. Fifth, earlier clinical trials indeed did not use angioplasty,
hich is the state-of-the-art technique. Sixth, whether the mode
f action is dependent on reperfusion type cannot be answered
ithout comparative studies. However, these earlier fibrinolytic
rials used much more insensitive surrogate parameters, and the
ample size was very small, which raises questions of power.
In general, we agree with Prof. Sochman that our LIPSIA-N-
CC trial should stimulate further research regarding oxidative
tress and also a large-scale clinical trial of NAC for CIN
revention. However, we strongly believe, on the basis of our
esults, that a general application of NAC in infarction patients
annot be recommended.
Holger Thiele, MD
Department of Internal Medicine/Cardiology
niversity of Leipzig–Heart Center
trümpellstrasse 39
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ermany
-mail: thielh@medizin.uni-leipzig.de
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ssessing Clinical Utility of
arotid Intima-Media Thickness
n the Basis of Reclassification
lthough Nambi et al. (1) report significant net reclassification
NRI) with the use of carotid ultrasound of 9.9% in the overall
RIC (Atherosclerosis Risk In Communities) cohort and 21.7%
n the intermediate-risk group (5% to 20% 10-year risk) and
onclude potential clinical utility in predicting cardiovascular
vents, the actual NRI tables for those with and without events
eed to be presented for full assessment of clinical utility. The NRI
s determined by: 1) movement to higher risk categories among
hose with events; and 2) movement to lower risk categories among
hose without events (2). Although both components of the NRI
re of interest, reclassification rates among those with events
epresent the more clinically relevant measure. However, Nambi et
l. (1) do not provide separate reclassification tables for those with
nd without events to assess where the reclassification is occurring.
urthermore, 2 categories were used for intermediate risk (5% to
0% and 10% to 20%), and it is unclear what drove the net
eclassification of 21% within this group: movement to 20%
redicted risk in those with events, movement to 5% predicted
isk in those without events, or movement within the 2 interme-
iate risk categories. Showing the actual NRI tables as described by
encina et al. (2) would aid clinical interpretation. Finally, coro-
ary revascularization and silent MI comprised 43% of the end
oints analyzed in the ARIC cohort; however, treatment changes
ould most likely occur for those with events who were reclassified
pward to 20% predicted 10-year risk of hard end points alone.
omplete assessment of clinical utility on the basis of improved
eclassification can only be assessed by showing the full NRI tables
or those with and without hard end points.
Anand Rohatgi, MD
arett D. Berry, MD, MS
Division of Cardiology
niversity of Texas Southwestern Medical Center
323 Harry Hines Boulevard
oom HA9.133
allas, Texas 75390-9047
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arotid Plaque Assessment
Bumpy Road to
mproved Risk Prediction
e congratulate Nambi et al. (1) on their study of improved
rediction of coronary heart disease (CHD) risk by including the
nformation on carotid plaque presence in the ARIC (Atheroscle-
osis Risk In Communities) study. Inclusion of plaque in the risk
rediction model reclassified over 10% of individuals into the
igher risk category beyond the levels of carotid intima-media
hickness (CIMT) and traditional risk factors. The study is
ignificant because the ARIC investigators acknowledge that
mall, nonstenotic carotid plaque might be a different phenotype of
therosclerosis, carrying an important contribution to the vascular
isk beyond CIMT. Plaque presence was defined if 2 of the
ollowing 3 criteria were met: CIMT 1.5 mm, abnormal wall
hape, and abnormal wall texture. This is a somewhat novel
pproach, because Dr. Ward A. Riley (a reputable CIMT and
RIC investigator who unfortunately is no longer with us) believed
hat “whatever is between intima and media represents CIMT” (Dr.
ard A. Riley, personal communication, 2001). In the recent CIMT
eta-analysis (2) very little is mentioned regarding the difference
etween CIMT and plaque and the prognostic importance of carotid
laque. Carotid plaque is a distinctive phenotype of atherosclerosis,
ost likely is not a simple continuum of CIMT progression, and
redicts stroke and CHD risk better than CIMT (3).
Interestingly, the ARIC investigators report that slightly more
ubjects were reclassified to a lower risk group (approximately 12%)
han to a higher risk group (approximately 11%) after adding
IMT and plaque information. No one was reclassified from the
ow-risk group (5% estimated 10-year CHD risk) to the high-
isk group (20% estimated 10-year CHD risk). In the NOMAS
Northern Manhattan Study)—a prospective, multi-ethnic, urban,
opulation-based cohort—the presence of small, nonstenotic ca-
otid plaque reclassified 44% of the low-risk individuals (10%
stimated 10-year CHD risk) to the intermediate-risk category
10% to 20% estimated 10-year risk) (4). In addition, approxi-
ately 12% of subjects in a lower risk category had a 10-year
stimated risk of 25%, which reclassified these individuals to high
isk (20% estimated 10-year risk). None of the individuals was
eclassified to a lower risk category after adding information on
laque presence—as opposed to ARIC. The NOMAS results are,
owever, hardly ever cited, possibly because they appeared in
eurology, a journal mostly neglected by non-neurologists. There-
ore, “the intriguing hypothesis” raised by Stein and Johnson in the
ditorial Comment (5) that “carotid ultrasound could be used to
dentify persons at lower than apparent risk who might be
andidates for less intensive interventions” might be simply rejected
f data from NOMAS and others (6) are considered. sNevertheless, less intensive intervention should not be advised
ccording to ultrasound imaging data for individuals otherwise
stimated at intermediate-to-high vascular risk on the basis of
raditional vascular risk factors. We believe these individuals
hould be treated aggressively, irrespective of a possible lower risk
ccording to the information obtained by the levels of biomarkers,
ither imaging or soluble.
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eply
e thank Drs. Rohatgi and Berry and Rundek and Salameh for
heir interest in our communication regarding the use of carotid
ntima media thickness (CIMT) and plaque to improve coronary
eart disease (CHD) risk prediction in the ARIC (Atherosclerosis
isk In Communities) study (1).
It is important to note that our study tested whether CIMT and
laque can help better predict CHD risk, but it does not have the
bility to offer guidance on treatment strategies on the basis of such
risk prediction scheme. Therefore, we completely agree with Drs.
undek and Salameh that, on the basis of our data alone, one
hould not decide on decreasing interventions. However, we feel
hat such a strategy should be prospectively tested, as has been
uggested by Drs. Stein and Johnson in the editorial that accom-
anied our publication (2). Drs. Rundek and Salameh also discuss
heir excellent contribution from the NOMAS (Northern Man-
attan Study) (3), in which they examined the value of adding
laque to the Framingham risk prediction score (FRS). However,
ome important facts/differences need to be considered.
